Takeda has revealed that it is set to bolster its novel immuno-oncology portfolio with three new research collaborations. The Japanese pharmaceutical firm has struck an alliance with the Memorial Sloan Kettering Cancer Center (MSK) in New York City, while also expanding two existing partnerships.
The deal with MSK will focus on the discovery and development of CAR-T drug products to treat blood cancers and solid tumours, including multiple myeloma and acute myeloid leukaemia.
